Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 12, 2010, Pages 1525-1532

  Mendes, F E S ^a   Oliveira, L V N ^a   Faria, E S ^a   Alvarenga, D G ^a   Pinto, M R ^b   Taborda, C P ^b   Soares, B M ^c   Cisalpino, P S ^c   Santos, D A ^b,c  

^a UNIVERSIDADE VALE DO RIO DOCE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; ITRACONAZOLE; TERBINAFINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOASSAY; BRAIN INFECTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DRUG BRAIN LEVEL; FUNGUS GROWTH; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWISS WEBSTER MOUSE;

ANIMALS; ANTIFUNGAL AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 78651333572     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-1034-8     Document Type: Article

References (29)

1. AE Brouwer P Teparrukkul S Pinpraphaporn RA Larsen W Chierakul S Peacock N Day NJ White TS Harrison 2005 Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis J Infect Dis 192 681 684 10.1086/432073 16028138 (Pubitemid 41099318)
2. KL Mershon A Vasuthasawat GW Lawson SL Morrison DO Beenhouwer 2009 Role of complement in protection against Cryptococcus gattii infection Infect Immun 77 1061 1070 1:CAS:528:DC%2BD1MXis1aisL4%3D 10.1128/IAI.01119-08 19114546
3. N Jain L Li DC McFadden U Banarjee X Wang E Cook BC Fries 2006 Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system Infect Immun 74 896 903 1:CAS:528:DC%2BD28XhtlahsL0%3D 10.1128/IAI.74.2.896-903. 2006 16428732 (Pubitemid 43185522)
4. A Gomez-Lopez O Zaragoza M Dos Anjos Martins MC Melhem JL Rodriguez-Tudela M Cuenca-Estrella 2008 In vitro susceptibility of Cryptococcus gattii clinical isolates Clin Microbiol Infect 14 727 730 1:CAS:528: DC%2BD1cXovFeku7s%3D 10.1111/j.1469-0691.2008.02021.x 18558948 (Pubitemid 351837036)
5. ZU Khan HS Randhawa W Chehadeh A Chowdhary T Kowshik R Chandy 2009 Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole Int J Antimicrob Agents 33 559 563 1:CAS:528:DC%2BD1MXkvVSks70%3D 10.1016/j. ijantimicag.2008.11.007 19195846
6. SS Kim HT Im IM Kang HS Lee HW Lee SH Cho JB Kim KT Lee 2007 An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study J Chromatogr B 852 174 179 1:CAS:528:DC%2BD2sXmtVGnurc%3D 10.1016/j.jchromb.2007.01.012 (Pubitemid 46830110)
7. CH Koks PL Meenhorst MJ Hillebrand A Bult JH Beijnen 1996 Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules Antimicrob Agents Chemother 40 1935 1937 1:CAS:528:DyaK28Xks12qu7o%3D 8843308
8. SC Harris JE Wallace G Foulds MG Rinaldi 1989 Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection Antimicrob Agents Chemother 33 714 716 1:CAS:528:DyaL1MXktVSjuro%3D 2546489
9. V Porta KH Chang S Storpirtis 2005 Evaluation of the bioequivalence of capsules containing 150 mg of fluconazole Int J Pharm 288 81 86 1:CAS:528:DC%2BD2cXhtFahs7%2FJ 10.1016/j.ijpharm.2004.09.013 15607260 (Pubitemid 39656457)
10. RA Larsen M Bauer AM Thomas JR Graybill 2004 Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis Antimicrob Agents Chemother 48 985 991 1:CAS:528:DC%2BD2cXitVGhtLg%3D 10.1128/AAC.48.3. 985-991.2004 14982793 (Pubitemid 38280353)
11. DA Santos JS Hamdan 2007 In vitro activities of four antifungal drugs against Trichophyton rubrum isolates exhibiting resistance to fluconazole Mycoses 50 286 289 1:CAS:528:DC%2BD2sXoslGmu70%3D 10.1111/j.1439-0507.2007. 01325.x 17576321 (Pubitemid 46920266)
12. M Cuenca-Estrella JL Rodriguez-Tudela 2002 Should antifungal treatments be based upon results of antifungal susceptibility testing? Rev Iberoam Micol 19 133 138 12825990
13. Clinical and Laboratory Standards Institute (CLSI) (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M27-A2. CLSI, Wayne, PA
14. RA Larsen M Bauer AM Thomas A Sanchez D Citron M Rathbun TS Harrison 2005 Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans Antimicrob Agents Chemother 49 3297 3301 1:CAS:528:DC%2BD2MXntFChtbs%3D 10.1128/AAC.49.8.3297-3301.2005 16048939 (Pubitemid 41060574)
15. AH Groll H Kolve 2004 Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy Eur J Clin Microbiol Infect Dis 23 256 270 1:STN:280:DC%2BD2c3gtVWgtA%3D%3D 10.1007/s10096-004-1108-6 15015031 (Pubitemid 38669937)
16. BM Soares DA Santos LM Kohler G da Costa César IR de Carvalho M dos Anjos Martins PS Cisalpino 2008 Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing Rev Iberoam Micol 31 242 245 10.1016/S1130-1406(08)70057-3
17. VT Figueiredo D de Assis Santos MA Resende JS Hamdan 2007 Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections Mycopathologia 164 27 33 1:CAS:528:DC%2BD2sXmvVyqu7c%3D 10.1007/s11046-007-9027-6 17551848 (Pubitemid 46988163)
18. O Lortholary M Nicolas S Soreda L Improvisi O Ronin O Petitjean B Dupont M Tod F Dromer 1999 Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing J Antimicrob Chemother 43 817 824 1:CAS:528:DyaK1MXktVykurs%3D 10.1093/jac/43.6.817 10404321 (Pubitemid 29273732)
19. HRN Salgado CCGO Lopes MBB Lucchesi 2006 Microbiological assay for gatifloxacin in pharmaceutical formulations J Pharm Biomed Anal 40 443 446 1:CAS:528:DC%2BD28XovVSktw%3D%3D 10.1016/j.jpba.2005.07.020 16139980 (Pubitemid 43143352)
20. PMA Lima ND Prado MLM Silva RDL Diniz KM Queiroz C César Ida GA Pianetti DA Santos 2009 Determination of ketoconazole in capsules by high-performance liquid chromatography and microbiological assay J AOAC Int 92 1076 1081 1:CAS:528:DC%2BD1MXhtVGhtbrK 19714975
21. DM Diamond M Bauer BE Daniel MAE Leal D Johnson BK Williams AM Thomas JC Ding L Najvar JR Graybill RA Larsen 1998 Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis Antimicrob Agents Chemother 42 528 533 1:CAS:528:DyaK1cXhvV2kt7w%3D 9517927
22. RA Larsen M Bauer JM Weiner DM Diamond MAE Leal JC Ding MG Rinaldi JR Graybill 1996 Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis Antimicrob Agents Chemother 40 2178 2182 1:CAS:528:DyaK28XlsVCgsL8%3D 8878602
23. WR Kirkpatrick LK Najvar R Bocanegra TF Patterson JR Graybill 2007 New guinea pig model of cryptococcal meningitis Antimicrob Agents Chemother 51 3011 3013 1:CAS:528:DC%2BD2sXoslOis7w%3D 10.1128/AAC.00085-07 17562797 (Pubitemid 47206249)
24. AMF Almeida MT Matsumoto LC Baeza RB de Oliveira E Silva AAP Kleiner SC Melhem Mde MJ Mendes Giannini Laboratory Group on Cryptococcosis 2007 Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from São Paulo State, Brazil FEMS Yeast Res 7 152 164 1:CAS:528:DC%2BD2sXhslyhu7w%3D 10.1111/j.1567-1364.2006.00128.x 17311593 (Pubitemid 46122040)
25. E Alvarado-Ramírez JM Torres-Rodríguez M Sellart V Vidotto 2008 Laccase activity in Cryptococcus gattii strains isolated from goats Rev Iberoam Micol 25 150 153 10.1016/S1130-1406(08)70035-4 18785783
26. SP Franzot JS Hamdan 1996 In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs Antimicrob Agents Chemother 40 822 824 1:CAS:528:DyaK28XhsVersro%3D 8851624
27. B Posteraro M Sanguinetti D Sanglard S La Sorda S Boccia L Romano G Morace G Fadda 2003 Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole Mol Microbiol 47 357 371 1:CAS:528:DC%2BD3sXos1Sjug%3D%3D 10.1046/j.1365-2958.2003.03281.x 12519188 (Pubitemid 36121027)
28. CF Orsi B Colombari A Ardizzoni S Peppoloni R Neglia B Posteraro G Morace G Fadda E Blasi 2009 The ABC transporter-encoding gene AFR1 affects the resistance of Cryptococcus neoformans to microglia-mediated antifungal activity by delaying phagosomal maturation FEMS Yeast Res 9 301 310 1:CAS:528: DC%2BD1MXisFGjsr4%3D 10.1111/j.1567-1364.2008.00470.x 19220870
29. L Einsiedel DL Gordon JR Dyer 2004 Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman Clin Infect Dis 39 e78 e82 10.1086/424746 15486830